Staffing: 2024’s Biggest Lab Operations Challenge
ADLM president Anthony Killeen looks at labs’ staffing struggles in 2024 and what can be done to alleviate them in the coming year
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
ADLM president Anthony Killeen looks at labs’ staffing struggles in 2024 and what can be done to alleviate them in the coming year
The Hilden, Germany-based company is extending its genetic testing profile beyond oncology to neurology biomarkers.
The agency recently stated that current testing capacity is adequate and established limits on its review of new EUA submissions.
ACLA and public health experts warn that current reimbursement rates will hamper US efforts to contain monkeypox spread.
Congress reportedly set to pass a stripped-down version of the FDA user fees bill without the VALID Act component regulating LDTs.
On August 21, the FDA proposed new guidelines on charging for investigational drugs; here are the key highlights.
Revised final rule essentially disarms the threat of insurers having the advantage in out-of-network price disputes.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.
In a surprise move, the e-retail giant announced it will close down its Amazon Care Primary Health Services for employees at the end of 2022.
While the rule is not yet final, it’s likely that labs will have to pay more in direct CLIA compliance expenses, starting in October.
While not nearly as robust as a year ago, diagnostic companies’ revenues held up surprisingly well in Q2 2022.